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Background: Patients with HIV are living longer due to the advent of highly active antiretroviral therapy
(HAART). Before this therapy, admission to the intensive care unit (ICU) was perceived by some patients
and providers to be an effort in futility. Now, outcomes appear to be improving for HIV infected patients
living in the HAART era. There is no set standard among providers of whether or not to continue or begin this
therapy in the intensive care unit. This medication has both benefits, such as bolstering patient’s immune
system, and drawbacks, such as problems with adverse effect and drug to drug interactions. Currently, there is
an unanswered question on whether or not continuing or starting this medication will improve mortality in
the ICU for HIV patients.
Clinical Question: Does the use of highly active antiretroviral medications reduce the mortality of patients in
the ICU. Study Design: Exhaustive search of available medical literature.
Methods: The focus of this study was to review current literature pertaining to highly active antiretroviral
medication in HIV infected patients in the intensive care unit which looked at mortality rate of patients
continuing, starting, or not using highly active antiretroviral therapy in the ICU.
Results: An exhaustive literature search yielded two retrospective cohort studies specific for the clinical
question. There were no randomized clinical trials on the topic. Both studies determined that patients on
highly active antiretroviral therapy had decreased mortality rates in the intensive care unit. Patients with
previous HAART use had the lowest mortality rate, followed by patients started on HAART. Finally patients
receiving no HAART did the worst.
Conclusion: This is an understudied evolving topic. More studies need to be implemented.
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Abstract   
 
Background: Patients with HIV are living longer due to the advent of highly active 
antiretroviral therapy (HAART). Before this therapy, admission to the intensive care unit 
(ICU) was perceived by some patients and providers to be an effort in futility. Now, 
outcomes appear to be improving for HIV infected patients living in the HAART era. 
There is no set standard among providers of whether or not to continue or begin this 
therapy in the intensive care unit. This medication has both benefits, such as bolstering 
patient’s immune system, and drawbacks, such as problems with adverse effect and drug 
to drug interactions. Currently, there is an unanswered question on whether or not 
continuing or starting this medication will improve mortality in the ICU for HIV patients. 
Clinical Question: Does the use of highly active antiretroviral medications reduce the 
mortality of patients in the ICU. Study Design:  Exhaustive search of available medical 
literature. Methods: The focus of this study was to review current literature pertaining to 
highly active antiretroviral medication in HIV infected patients in the intensive care unit 
which looked at mortality rate of patients continuing, starting, or not using highly active 
antiretroviral therapy in the ICU. Results:  An exhaustive literature search yielded two 
retrospective cohort studies specific for the clinical question. There were no randomized 
clinical trials on the topic. Both studies determined that patients on highly active 
antiretroviral therapy had decreased mortality rates in the intensive care unit. Patients 
with previous HAART use had the lowest mortality rate, followed by patients started on 
HAART. Finally patients receiving no HAART did the worst. Conclusion: This is an 
understudied evolving topic. More studies need to be implemented.  
 
Keywords:  HIV, HAART, antiretroviral therapy, intensive care unit, and critical care 
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For Adult HIV Patients on Highly Active Antiretroviral Therapy, Will Continuation or 
Initiation of Therapy in Intensive Care Units Improve Patient Outcome During 
Hospitalization When Compared to Patients Not Receiving Therapy 
 
 
Introduction 
     Highly active antiretroviral therapy (HAART) is changing the course of HIV infection 
from a death sentence to a chronic illness 1-3. This is especially true in developed 
countries, where the medications are more readily available. Studies have shown, that 
HIV infected people in the HAART era have a decline in rates of AIDS infections and a 
“significant decrease in mortality and increase in life expectancy” 4-6 While improving 
patient’s life expectancy, HAART is also changing the face of intensive care unit (ICU) 
admission for HIV infected patients. Providers are now presented with more questions 
than just a decision whether to admit an HIV patient to the ICU. They are faced with 
whether to stop, start, or continue HAART during the patient’s hospital course. 
     According to the center for disease control (CDC) patients with AIDS have 
“laboratory-confirmed evidence of HIV infection in addition to a CD4+ T-lymphocyte 
count of <200 cells/µL, a CD4+ T-lymphocyte percentage of total lymphocytes of <14, 
or diagnosis of an AIDS-defining condition “7. An opportunistic infection (OI) is an 
infection that occurs as a result of compromised immune system. OI’s do not typically 
occur in people with healthy immune systems.  HIV was first described in 1981 when 
cases of OI’s such as Kaposi Sarcoma (KS) and Pneumocystic Carini Pneumonia (PCP) 
began appearing in young, seemingly healthy homosexual men in Los Angeles, New 
York, and San Francisco. Intravenous drug users, heterosexual partners of affected 
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patients and some blood transfusion recipients also began developing similar OI’s. This 
fueled the search for a serologic cause and thus, HIV was discovered in 1984 to be the 
transmissible agent 8.    
     Medical providers began to use HAART to treat HIV/AIDS patients in the mid 
1990’s. It is defined as having three antiretroviral medications from at least two of the 
different groups (Table 1). Studies divide the HIV/AIDS timeline into the pre HAART 
era and the HAART era 9-11. Pre HAART is defined as the time when AIDS was first 
diagnosed in 1981 through 1996 when few antiviral medications were available. HAART 
is the period from 1996 to present. Although some antiretroviral medications were being 
utilized, the official HAART era did not begin until protease inhibitors were introduced 
and made publicly available 12-14. Currently, there are more than 20 antiretroviral 
medications on the market. The three major classes of medications are: 
• Nucleoside (and nucleotide reverse transcriptase inhibitors (NRTIs) 
• Nonnucleoside reverse transcriptase inhibitors (NNRTIs) 
• Protease inhibitors (PIs).12 
        The goals of antiretroviral therapy, according to the department of health and human 
services, are: 
• To reduce morbidity and mortality and prolong survival. 
• To improve quality of life 
• To Restore and preserve immunologic function 
• To maximally and durably suppress viral load 
• To prevent vertical HIV transmission 15. 
 8 
NRTIs interfere with the reverse transcriptase enzyme suppressing replication of 
retroviruses. They cause premature termination of the viral precursor chain. With the 
exception of lamivudine and abacavir, this class of medication is associated with 
potentially fatal liver toxicities such as lactic acidosis and hepatotoxicities 12 . 
     NNRTIs bind to HIV reverse transcriptase, inducing a conformational change which 
results in enzyme inhibition. The drugs commonly have drug to drug interactions and a 
high incidence of hypersensitivity reactions, including rash. Some NNRTIs can  inhibit 
Cytochrome P34A isoenzyme of cytochrome P450, resulting in possible toxic 
accumulations of drugs that rely on cytochrome P450 metabolism for their termination of 
action 12 
     PI’s work by inhibiting the HIV aspartyl protease, which is an enzyme used in the 
production of new viruses. Common adverse effects are parasthesias, nausea, vomiting 
and diarrhea. They can also cause disturbances in glucose and lipid metabolism resulting 
in hypercholesterolemia and diabetic complications. PI’s are also inhibitors of the 
CYP34A isoenzyme of cytochrome P450 12. 
     A study performed by Mok et al, to evaluate drug interactions that commonly occur in 
hospitalized patients on HAART, found that 86% of their patients had at least one drug 
related problem 16. They also found Atazanavir, a protease inhibitor, to be the most 
commonly implicated medication. Furthermore, they reported that of the twenty three 
drug to drug interactions involving atazanavir, 11 occurred with proton pump inhibitors 
or histamine-2 blockers. Therefore, while the CDC shows a decrease in morbidity and 
mortality since the formal introduction of the medication 17, the medications are not 
without complications. 
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     The possible side effects and adverse reactions of HAART are numerous. Lactic 
acidosis, Hypersensitivity syndromes, hepatitis and immune reconstitution inflammatory 
syndrome (IRIS) manifest during therapy (Table 2). These issues can be difficult to 
distinguish from other non HAART related medical illnesses in hospitalized patients 18.  
These, in addition to dosing complications, give rise to the question of whether or not to 
utilize the medications in critically ill patients during their ICU course.18, 19 
     In the pre HAART era providers were faced with the difficult task of whether or not to 
admit a patient to the ICU with an AIDS related opportunistic infection (OI). Providers 
often viewed admission as an effort in futility. 1, 2, 18. In this era, the prognosis of OI’s 
was typically grim 1, 2. The HARRT era has seen a decrease in the admission of patients 
with OIs, while the ICU admission rates have remained relatively stable according to one 
study 11, and shown slight increase in others 1, 18, 20. There has been speculation that 
admissions have remained stable or increased because in the pre HAART era patients 
with OIs were not referred to ICU, while currently with the use of HAART, patients have 
an improved outcomes with ICU admissions, leading to more aggressive treatments 18. 
Typical ICU admissions in the pre HAART era were Pneumocystis Carini pneumonia 
(recently renamed pneumocystis jiroveci pneumonia),  Mycobacterium avium complex 
(MAC), cytomegalovirus (CMV) toxoplasmosis, and tuberculosis (TB)21. Currently, 
while studies indicate respiratory failure is still the number one reason for admission, the 
rate of PCP is decreasing and non HIV related reasons for admissions are increasing 1, 11, 
20. Although some studies indicate there is no improvement for outcome of patients 
receiving HAART prior to hospital admission 3, 9, other studies have shown HAART to 
be beneficial to ICU outcomes, as well as to long term outcomes for patients already on 
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therapy 1, 4, 10, 11, 13, 22, 23. One particular study at San Francisco General Hospital (SFGH) 
published in 2003, showed a resulting decrease in mortality and as a reason to start 
HAART for patients with PCP in the ICU22.  
Whether or not to continue HAART in the ICU is a current debate among many 
providers. There are few studies relating to the use of HAART in ICU patients and there 
have been no randomized clinical trials. The complications of administration, the cost of 
HAART, the possible side effects and drug interactions of HAART initially lead to the 
decision to discontinue therapy for patients in the ICU. Now, however, with more studies 
showing improved outcomes for patients having previously received HAART, because 
they are healthier at the time of admission and two published studies showing positive 
effects of therapy in ICU patients, whether or not to continue or initiate therapy is worthy 
of further study.    
Methods 
     An exhaustive literature search was performed using Medline, CINAHL, Pubmed, 
MD Consult, StatRef and web of science in the Pacific University library server. The 
search terms HIV, HAART, antiretroviral therapy, ICU and critical care were employed 
in various combinations. A very low inclusion criteria on study endpoints was utilized 
due to lack of studies available on an evolving topic. Any study done after 1996, 
specifically involving HAART administration in HIV patients in the ICU, whether 
beginning treatment or continuing was included. Exclusion criteria were studies which 
did not specify whether or not patients continued or received therapy in ICU and studies 
printed in foreign languages.  Numerous studies were found involving HAART and HIV 
ICU patients. Of the twenty, two met the inclusion and exclusion criteria for the paper.      
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RESULTS 
 
    A retrospective cohort study done by Morris et al at San Francisco General Hospital in 
San Francisco, evaluated 58 HIV infected adults admitted to the ICU. The study was a 
standardized chart review for the years 1996-2001 that assessed mortality while in the 
ICU or hospital for HIV infected patients admitted with Pneumocystis carinii pneumonia 
(PCP). The patients were divided into three subgroups, those receiving HAART prior to 
admission and continued, patients started on HAART in ICU, and patients not receiving 
HAART. The study found a mortality rate of 16.7% (on HAART), 33.3% (starting 
HAART) and 63.0% (no HAART) respectively. Overall the mortality rate between 
patients receiving HAART in ICU versus patients not receiving HAART was 25.0% to 
63.0%. 
     A 2009 study found was done at a tertiary care teaching hospital in Sao Paulo, Brazil. 
Croda et al. performed a retrospective cohort study measuring in ICU mortality and 6 
month mortality in HIV infected patients on, off, or started on HAART therapy. The 
study evaluated a total of 278 HIV infected patients admitted to the ICU. The study found 
that the use of antiretroviral therapy (ART; Croda et al uses ART interchangeably with 
HAART) “was more beneficial to patients with a history of previous ART use (HR=0.46 
[95%CI 0.25-0.84].” While patients without use of ART have a HR=0.92 [95%CI 0.58-
1.46]. It was also found that patients who received ART and discontinued therapy during 
ICU admission had a higher mortality risk with HR=2.00 [95%CI 0.30-1.53] when 
compared with patients who continued ART in ICU; HR=1.00 [95%CI 0.30-0.98]. The 
study found in a subgroup analysis that, “ART remained a significant negative risk factor 
of mortality” comparing patients started on ART during the ICU stay, with patients who 
 12 
did not receive ART resulting in HR=.55 [95%CI 0.31-0.98]. Of the patients started on 
ART, 18.1% were found to have adverse reactions, which resulted in either a switch or 
discontinuation of ART therapy. Mortality did not appear to be different among patients 
with continuous ART versus patients who interrupted or modified ART during the 
hospital course. 
DISCUSSION 
     With the advent of HAART, life expectancy among HIV patients has increased 4-6. An 
increasing number of studies are showing an improvement in the outcome of patients 
presenting to the ICU with HIV and a wider variety in reasons for admission 4, 11, 23. The 
number one diagnosis for HIV patients presenting to the ICU is still respiratory failure 
but other conditions such as liver failure, gastrointestinal bleeds, and cardiac issues are 
increasing 1, 6, 11, 20, 22. In the Pre HAART era, many physicians wrestled with the idea of 
admitting patients with OI’s due to perceived futility of doing so 22. Now admissions are 
extremely common as outcomes improve 22One of the biggest controversies around HIV 
patients in the ICU is HAART. The decision whether or not to continue HAART in a 
patient admitted to the ICU remains a difficult one. There is the additional question of the 
appropriateness of beginning HAART under these circumstances. There are arguments 
for and against each of these options (Table 3). 
      HAART reduces viral load and increases CD4 counts in patients. This has a positive 
effect on the function of the immune system, making the patients less susceptible to 
opportunistic infections5, 21, 24. This is favorable in any hospital setting, but especially in 
the ICU. The incidence of pneumonia, both community acquired and hospital acquired 
has been shown to be greatly reduced in patients on HAART 25. Also, if HAART is 
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discontinued in patients, there is risk for a rebound effect of stopping the medication, 
with an immediate decrease in CD4 count and increase in viral load14 . This can make 
patients more susceptible to secondary infections, or to worsening of their presenting 
illness 14. Discontinuation may also result in viral resistance to HAART6, 14, 16, 18. NNRTIs 
have a longer half life then other antiretroviral medications. Abruptly discontinuing 
medication in HAART without accounting for the long half life of the NNRTI can result 
in monotherapy which can lead to a viral strain resistance to the medication regimen 6, 16, 
18, 19.  Finally, starting HAART in PCP has shown a positive effect on CD4 counts and 
decreased viral load while reducing mortality according to Morris et al.  
        Continuing HAART, however, is not without problems. The regimen is extremely 
difficult to maintain in ICU patients, who are typically unable to eat. Some of the 
medications require food for absorption, while others need to be taken on an empty 
stomach. This presents problems in the ICU for patients on continuous tube feedings. 
Medications such as saquinivir, a protease inhibitor, require high fat meals for absorption. 
This is in direct contrast to amprenavir, a protease inhibitor, where high fat meals should 
be avoided 18, 19. Administration of medications can also cause issues. Only Zidovudine, 
an NRTI,can be given intravenously6. Some medications come in oral suspension, while 
others can be crushed and both can be given via gastric tube.  Still, others have to be 
taken whole for appropriate absorption due to their enteric coatings. Patients in ICU are 
also typically on proton pump inhibitors (PPI) for stress ulcer prophylaxis. Many 
HAART medications need stomach acids for absorption, which conflicts with the PPI 
regimen, making continuing appropriate medication dosages difficult 6, 18, 19. Due to their 
side effects, HAART medications can also cause new problems in ICU patients. This can 
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make it difficult for clinicians to distinguish between worsening of a patient’s conditions 
due to progression in the presenting illnesses, or a compounding complication due to 
HAART18, Some HAART medications also interfere with the cytochrome P45A, an 
isoenzyme of cytochrome P450, which results in problems of metabolizing other drugs, 
particularly medications used in the ICU (table 4). Finally, when starting patients on 
HAART, there is a chance of immune reconstitution inflammatory syndrome 
development (IRIS). 
    IRIS is a syndrome that can develop when a person is started on HAART, and is a 
“paradoxical worsening of preexisting, untreated, or partially treated opportunistic 
infections”26. It is an inflammatory response resulting from an improvement in a patients 
immune system due to antiretroviral medications and is most commonly seen in patients 
with mycobacterium tuberculosis, mycobacterium avium, PCP and endemic fungi 19. The 
symptoms can present anywhere from weeks to years after initiating therapy. Symptoms 
of IRIS are dyspnea, hypoxemia, fever and cough with new or worsened chest x ray 
findings 18, 27.  In the 2009 study published by Croda et al, three patients developed IRIS 
following initiation of HAART. According to the study however, it was not necessary to 
discontinue their therapy 13.   
     There are still no set standards for how HAART should be applied in the ICU setting. 
Numerous complications including medication interactions, absorption, administration, 
and adverse reactions including IRIS, all tend to lead providers to reject the use for 
HAART in the ICU.  Two recent studies however, have shown improved clinical 
outcomes for patients with the use of HAART in the ICU. Croda et al found a decrease in 
mortality among patients continuing, and starting on HAART while in the ICU. Morris et 
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al also found a decrease in mortality among patients with PCP continuing or starting 
HAART in the ICU. Both had similar patient characteristic information. Median age for 
Morris et al was 36.6 in HAART users and 41.6 for non HAART. Croda et al reported a 
median age of 39.4 and the majority of patients in both studies were male (greater than 
70%). Both studies utilized multivariate regression analysis to determine variables of 
predictive in hospital analysis. Both studies also reported mechanical ventilation within 
the first twenty-four hours to be an independent predictor of patient mortality. The 
limitations of these studies were similar in that they were not broad in their patient 
spectrum. Both studies were retrospective cohort studies obtained at specific institutions. 
Morris et al only surveyed 58 patients over the course of the 5 year study and there was 
no follow up. Croda et al included 278 patients with a 6 month follow up.  Both studies 
similarly acknowledge, due to the retrospective cohort nature of their studies, 
unmeasured factors may have contributed to the difference in survival. Both studies also 
acknowledge that hospital polices, admission, discharge practices and practice patterns of 
staff may result in differing outcomes with other institutions. Variations in patient 
populations and adherence to prior HAART as well as post HAART adherence can have 
an effect of patient outcome which is difficult for retrospective cohort studies to take into 
consideration.  
Limitations of Review 
An exhaustive literature search yielded only 2 specific articles pertaining to actual 
HAART use in ICU patients. There have been no randomized clinical trials. This is an 
understudied area.  
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Conclusion 
    The argument as to whether or not to continue HAART in ICU patients is far from 
resolved. There is no set standard of care and the decision on whether to start or continue 
therapy is left to specific institutions and providers. The newest study from Croda et al 
shows improved mortality in ICU patients continuing or starting HAART. It is evidence 
that more studies need to be performed in this area with broader patient populations to 
reach a consensus on providing the best possible outcome for patients. 
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Tables 
 
Table 1. Highly Active Antiretroviral Therapy 
 
HAART 
Two nucleoside/tide reverse transcriptase inhibitors 
Plus 
One protease inhibitor 
 
OR 
Two nucleoside/tide reverse transcriptase inhibitors 
Plus 
One non-nucleoside reverse transcriptase inhibitor 
 
Table 2 .Antiretroviral Medication Side Effects* 
 
Side Effect Drugs 
Lactic acidosis Nucleoside reverse transcriptase inhibitors, 
especially didanosine and stavudine 
Hypersensitivity reactions Abacavir, neviripine 
Liver toxicity Saquinavir, ritonavir, nelfinavir, tenofovir, 
evirapine, efavirenz, atazanavir 
Pancreatitis Didanosine, stavudine, zalcitabine, 
lopinavir/ritonavir 
Nephrolithiasis  Indinavir 
Acute tubular necrosis Tenofovir 
Acute interstitial nephritis Indinavir, ritonavir 
Myelosupression Zidovudine 
Myopathy Zidovudine 
Neuropathy Stavudine, didanosine, zalcitabine 
*18 
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Table 3. Potential Problems and Benefits of Antiretroviral Therapy in the Intensive Care 
Unit.* 
 
Potential Problems Potential Benefits 
Limited availability of intravenous or 
liquid medications. 
Immune reconstitution may improve 
prognosis. 
Erratic gastrointestinal absorption leading 
to sub therapeutic drug levels. 
Beneficial effects of viral suppression 
during acute illness. 
Potential HIV resistance. Decreased risk for subsequent 
opportunistic infections. 
Possibility of immune reconstitution 
inflammatory syndrome. 
 
Possible non compliance after discharge.  
Multiple drug interactions, side effects and 
overlapping toxicities. 
 
*18 
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Table 4. Common Antiretroviral Medication Interactions with Commonly Used Intensive 
Care Unit Medications. 
 
Drugs Antiretrovirals Interactions 
Midazolam/triazolam Most PIs, NNRTIs Increased sedative 
effects 
Methadone Most PIs, NNRTIs, NRTIs Narcotic 
withdrawal 
Meperidine Ritonavir Increased 
normeperidine 
Ergotamine  Amprenavir, delavirdine, efavirenz, 
indinavir, lopinavir/ritonavir, nelfinavir, 
ritonavir  
Ergotamine 
toxicity 
Metronidazole Amprenavir, Lopinavir/ritonavir, ritonavir Disulfram-like 
reaction 
Amiodarone Ritonavir Increased cardiac 
effects 
Diltiazem Amprenavir, atazanavir Increased cardiac 
effects 
Nifedipine Amprenavir, delavirdine,  
Lopinavir/ritonavir 
Increased cardiac 
effects 
Sildenafil PIs Increased 
sildenafil effects 
*18 
 
